Argenx buoyed by PhII trial results; Boehringer touts a big batch of real-world COPD data
→ Shares of Belgium’s argenx $ARGX edged up this morning as the company touted top-line data from its Phase II study of efgartigimod …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
